The SCiStar Study is a Phase 1/2a clinical trial evaluating the safety and activity of escalating doses of AST-OPC1 cells in newly injured patients with sensory and motor complete cervical spinal cord injury. The three patients in the first cohort were administered a low dose of 2 million cells to check for safety. Recruitment for the second cohort will begin immediately, with a planned enrollment of five patients who will each receive 10 million cells.
Asterias to begin stem cell dose escalation in the Phase 1/2a trial for SCI
Skip back to main navigation